Título original
Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for Untreated Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Título en castellano
Resultados del CCG-2961, un Estudio de Fase 3 para Niños no Tratados con Leucemia Mieloide Aguda: Informe del Grupo de Oncología Pediátrica

Palabras clave
leucemia mieloide aguda, niños, idarrubicina, monofosfato de fludarabina, interleuquina-2, ensayo de fase 3

Key Words
acute myeloid leukemia, children, idarubicin, fludarabine monophosphate, interleukin-2, phase 3 trial

Autores
Lange BJ, Smith FO, Alonzo TA

Dirigir correspondencia a:
BJ Lange, University of Pennsylvania School of Medicine Children's Hospital of Philadelphia, Filadelfia, Pensilvania, EE.UU.

Patrocinio
Subvenciones de National Institutes of Health; National Institutes of Health to Children´s Cancer Group Institutions; Yetta Dietch Novotny Chair in Clinical Oncology.

Institución
University of Pennsylvania School of Medicine